Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Promising long-term vaccine for Crimean-Congo hemorrhagic fever developed

Crimean-Congo hemorrhagic fever (CCHF) is one of the world's most dangerous yet overlooked infectious diseases.

22 Nov 2025

Marine bacterium shows powerful therapeutic effects against colorectal cancer

A research team led by Professor Eijiro Miyako at the Graduate School of Advanced Science and Technology, Japan Advanced Institute of Science and Technology (JAIST), has discovered that the marine bacterium Photobacterium angustum demonstrates remarkable therapeutic efficacy against colorectal cancer.

21 Nov 2025

Ultraprocessed diets affect teens and young adults differently

A study reveals that adolescents consume more calories on ultraprocessed diets, highlighting a critical vulnerability in modern food environments.

21 Nov 2025

Neoantigens-loaded DC vaccines show strong potential to overcome tumor resistance

Despite the success of immune checkpoint inhibitors in revolutionizing oncology, their benefits remain limited to a small fraction of patients.

19 Nov 2025

Enhancing the cancer-immunity cycle through innovative vaccines

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat malignancies.

14 Nov 2025

Scientists invent new method for manufacturing platelet-producing cells from stem cells

Platelets are small, disc-shaped cell fragments in the blood that are essential to stop bleeding and to initiate blood clotting after injury.

13 Nov 2025

Celleo Biotech uses INTEGRA's PIPETBOY GENIUS to improve reproducibility and efficiency

Celleo Biotech is using the PIPETBOY GENIUS serological pipet controller from INTEGRA Biosciences to streamline the development and manufacturing of novel cell and gene therapies.

From INTEGRA Biosciences 13 Nov 2025

Researchers achieve long-term remission with novel T cell therapies for HPV-related cancers

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI) - designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center of the National Institutes of Health, announced findings from two HPV-related studies that highlight the potential of novel T cell therapies to achieve long-lasting remission and complete tumor regression in patients with advanced epithelial cancers.

10 Nov 2025

BIOVECTRA and Revolution Biomanufacturing partner to deliver integrated mRNA Design and GMP production services

BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translational efficiency.

6 Nov 2025

Researchers use genetic engineering to create “product-ready” snakebite antivenom

An international team of researchers has used genetic engineering to create the first ever “product-ready” antivenom for snakes such as cobras and mambas.

4 Nov 2025

Even low PFAS in drinking water raise blood levels, California study shows

Researchers in Southern California found that even low levels of PFAS (“forever chemicals”) in public drinking water lead to measurable increases in blood PFAS concentrations. The study underscores the urgent need for stronger water-quality monitoring and stricter PFAS regulations across non-industrial regions.

2 Nov 2025

Novel nanoparticles can deliver an immune-stimulating molecule directly to ovarian tumors

Cancer immunotherapy, which uses drugs that stimulate the body's immune cells to attack tumors, is a promising approach to treating many types of cancer. However, it doesn't work well for some tumors, including ovarian cancer.

31 Oct 2025

Baby formula can harbor heat-resistant bacteria even after safe preparation

Research shows that powdered infant formula may contain microbial contaminants despite following 70°C preparation guidelines, highlighting potential risks.

31 Oct 2025

Purdue researchers develop 30-second vaccine quality tool

The outbreak of the COVID-19 pandemic demonstrated the need to rapidly develop, produce and distribute large quantities of new vaccines. A team of researchers at Purdue University and Merck & Co. Inc., known as Merck Sharp & Dohme Corp. outside of the U.S. and Canada, has now introduced a new analytical tool that could help pharmaceutical companies boost vaccine production with rapid monitoring and analysis.

29 Oct 2025

New technology improves the efficiency of protein production in E. coli

Proteins sourced from microorganisms are attracting attention for their potential in biomanufacturing a variety of products, including pharmaceuticals, industrial enzymes, and diagnostic antibodies.

28 Oct 2025

Advancements and clinical translation of intelligent nanodrugs for breast cancer treatment

A comprehensive review in "Biofunct. Mater." meticulously details the most recent advancements and clinical translation of intelligent nanodrugs for breast cancer treatment.

24 Oct 2025

How COVID mRNA vaccines may make cancer treatments more effective

Researchers found that COVID-19 mRNA vaccines, when given within 100 days of starting immune checkpoint inhibitors, were linked to significantly longer survival in lung and melanoma cancer patients. The vaccines trigger a powerful type-I interferon response that primes tumors to become more responsive to immunotherapy.

23 Oct 2025

New type of immunotherapy could change the treatment plan for triple-negative breast cancer

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful therapies.

22 Oct 2025

Epigenetic editing enables safer and more effective T cell therapies

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary human T cells, addressing a key manufacturing and scalability challenge in next-generation cell therapies.

21 Oct 2025

VICT3R project builds momentum to accelerate animal-free safety testing

The VICT3R project is expanding its consortium by adding new beneficiaries and organisations to the network of contract research organisations (CROs) associated with the project.

16 Oct 2025